Pharmaceutical research - Germany as a location with high innovative power

For the development and research of new drugs, pharmaceutical companies need staying power and a high willingness to take risks:

From 5,000 to 10,000 tested substances, only one makes it into the approval process. According to the VCI (German Chemical Industry Association), 1.8 billion euros will be invested in drug research and clinical studies in Germany in 2018. And the trend is rising.

However, 1/3 of the world's pharmaceutical and chemical research publications already come from Singapore. South Korea are also new competitors in pharmaceutical research.

The progress in Big Data in the pharmaceutical industry must be kept up to date. Many companies use their own software to specifically develop drugs for patients and reduce research costs. The knowledge gained by structuring data can accelerate drug development.

According to the vfa (Association of Research-based Pharmaceutical Companies), one of the advantages of being located in Germany is the dense network of competent research institutions such as various universities and non-university institutions (for example, Max Planck, Leibniz and Fraunhofer Institutes and the Helmholtz Centres). Innovative biotech start-up companies are often founded from these institutes as spin-offs.

The representation of interests of research-based pharmaceutical companies reports: "Many vfa member companies see an important plus for their German locations in their well-trained, motivated and responsible employees. This applies to laboratory scientists, clinical developers, managers and engineers... In 2017, around 17,100 employees were working in R&D - about one fifth of the workforce".

A competent team of experts is a requirement to be at the forefront of the international race in preclinical and clinical research. With the BESTMINDS consultants at your side, you will find the qualified staff for your pharmaceutical research: